Open access
Sep 2026
Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United Kingdom
Sodium–glucose cotransporter-2 inhibitor (SGLT2i) dapagliflozin has shown favourable outcomes in trials for heart failure with reduced ejection fraction (HFrEF), but little is known about real-world prescribing practices, tolerability, or impact on patient quality of life (QoL) in the United Kingdom. This st...
Steven Coombs, Angela Tithecott, C. Thiebaud et al.
· Frontiers in Cardiovascular... · 0 citations